Trial Registration
This study was registered with This phase 1 study demonstrate the safety and efficacy of pyrotinib in HER2 positive GC. Pyrotinib alone and plus docetaxel are well‐tolerated and show anti‐tumor activity. But combination with docetaxel cannot improve the efficacy.
Dan Liu, Furong Kou, and Jifang Gong contributed equally.